Name | Number of supported studies | Average coverage | |
---|---|---|---|
retinal ganglion cell | 6 studies | 63% ± 18% | |
GABAergic neuron | 4 studies | 28% ± 11% | |
glutamatergic neuron | 3 studies | 28% ± 10% |
Insufficient scRNA-seq data for expression of SV2C at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 92% | 3004.64 | 2441 / 2642 | 35% | 1.46 | 250 / 705 |
prostate | 63% | 90.94 | 154 / 245 | 61% | 1.46 | 308 / 502 |
stomach | 94% | 222.86 | 337 / 359 | 6% | 0.13 | 17 / 286 |
ovary | 56% | 148.95 | 101 / 180 | 26% | 1.18 | 113 / 430 |
adrenal gland | 21% | 59.04 | 55 / 258 | 52% | 7.17 | 119 / 230 |
intestine | 47% | 65.29 | 455 / 966 | 4% | 0.09 | 23 / 527 |
esophagus | 28% | 42.71 | 410 / 1445 | 2% | 0.02 | 3 / 183 |
bladder | 19% | 28.05 | 4 / 21 | 6% | 0.12 | 28 / 504 |
breast | 22% | 22.48 | 101 / 459 | 2% | 0.03 | 18 / 1118 |
skin | 18% | 18.20 | 317 / 1809 | 3% | 0.13 | 15 / 472 |
spleen | 12% | 10.60 | 28 / 241 | 0% | 0 | 0 / 0 |
lung | 9% | 8.90 | 53 / 578 | 2% | 0.03 | 19 / 1155 |
uterus | 5% | 8.24 | 8 / 170 | 4% | 0.14 | 20 / 459 |
adipose | 8% | 7.60 | 95 / 1204 | 0% | 0 | 0 / 0 |
heart | 6% | 7.71 | 55 / 861 | 0% | 0 | 0 / 0 |
pancreas | 3% | 2.45 | 9 / 328 | 3% | 0.05 | 5 / 178 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.05 | 2 / 45 |
kidney | 2% | 2.94 | 2 / 89 | 1% | 0.03 | 7 / 901 |
blood vessel | 2% | 2.38 | 26 / 1335 | 0% | 0 | 0 / 0 |
thymus | 1% | 1.21 | 8 / 653 | 0% | 0.02 | 2 / 605 |
liver | 0% | 0.45 | 1 / 226 | 1% | 0.03 | 4 / 406 |
eye | 0% | 0 | 0 / 0 | 1% | 0.10 | 1 / 80 |
peripheral blood | 1% | 1.25 | 6 / 929 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.70 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_2000300 | Biological process | regulation of synaptic vesicle exocytosis |
GO_0055085 | Biological process | transmembrane transport |
GO_0006836 | Biological process | neurotransmitter transport |
GO_0030672 | Cellular component | synaptic vesicle membrane |
GO_0008021 | Cellular component | synaptic vesicle |
GO_0098691 | Cellular component | dopaminergic synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
GO_0022857 | Molecular function | transmembrane transporter activity |
Gene name | SV2C |
Protein name | Synaptic vesicle glycoprotein 2C |
Synonyms | KIAA1054 |
Description | FUNCTION: Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles. .; FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin type A (BoNT/A, botA); the toxin probably binds via extracellular loop 4 . Recognition by BoNT/A relies on both protein-protein and protein-N-glycosylation; glycosylation of Asn-559 increases its affinity for BoNT/A . Also serves as a receptor for the closely related C.botulinum neurotoxin type A2; glycosylation is not essential but enhances the interaction . .; FUNCTION: (Microbial infection) Possible receptor for C.botulinum neurotoxin type D (BoNT/D, botD); note that type D does not usually infect humans. . |
Accessions | Q496J9 ENST00000502798.7 B3KT41 ENST00000322285.7 |